NNVC,
NanoViricides Reports Initial Safety Results Regarding its Anti-Influenza and Bird Flu Drug
Monday November 7, 8:00 am ET
WEST HAVEN, Conn.--(BUSINESS WIRE)--Nov. 7, 2005--NanoViricides, Inc. (Pink Sheets:NNVC - News) announced that it has completed its initial safety studies on the major constituent of its anti-viral drug, FluCide-I(TM). The polymer which is unique and proprietary to NanoViricides, has been effectively tested for any toxic symptoms or for any ill effects in laboratory animals. The preliminary results were successful. More studies are being conducted for further detailed evaluations. The studies are being conducted at the Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School.
ADVERTISEMENT
The Company will follow these studies with preliminary pre-clinical evaluations of certain ligands designed to specifically target the drug to H5N1 (avian flu) as well as common influenza viruses.
The Company's management has deemed this drug development project as its most urgent priority and believes that should FluCide-I(TM) prove successful in pre-clinicals, the timeline for regulatory approval in the later phases can be significantly shortened. The Company is encouraged by reports in Saturday's Wall St. Journal that the "FDA's acting head said that he is assembling a team of agency experts who will work to approve both antivirals and vaccines that would treat a pandemic flu virus."
nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for anti-viral therapy. A nanoviricide(TM) is a specially designed, flexible, nanomaterial with or without an encapsulated active pharmaceutical ingredient and a targeting ligand to a specific type of virus, like a guided missile.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
--------------------------------------------------------------------------------
Contact:
NanoViricides, Inc.
Leo Ehrlich, 917-853-6440
leo@nanoviricides.com
--------------------------------------------------------------------------------
Source: NanoViricides, Inc.
Email Story
Set News Alert
Print Story
|
